Stage IIA Cutaneous Melanoma: Do Regional Ultrasound and CT scan Improve Detection of Relapses? A Multicenter Retrospective Observational Study

Abstract

Introduction: Stage 2A cutaneous melanoma is typified by a Breslow thickness between 1.1 and 2.0 mm with ulceration or between 2.1 and 4.0 mm without ulceration. The role of radiological investigations in staging and follow-up of this intermediate-risk subgroup of patients is still debated. Objective: The aim of this study is to investigate the role of imaging procedures in the follow-up of stage IIA melanoma asymptomatic patients. Methods: Data were retrieved from 2 tertiary referral centers in Italy. Among patients with stage 2A melanoma, those who relapsed were investigated concerning type of detection (by patient or by doctor), and modality of detection (clinical examination, ultrasound, CT scan). In addition, false positive data were collected. Results: In total, 213 patients were retrieved, with 26 patients showing relapse (recurrence rate, 12.2%). The mean follow-up time was 3 years and the mean time to recurrence was 17.8 months. 21/26 (80.7%) recurrences were identified by the doctor and 5/26 (19.2%) by the patient (p<0.05). Among those identified by the doctor, 16/21 (76.1%) were identified by radiological examinations. 9/15 (60%) lymph node recurrences were detected by ultrasound and 6/7 (85.7%) distant metastases were detected by CT. The false positive rate was 7% (p<0.05). Conclusions: In our study the great majority of metastases were detected using imaging procedures. Given the new therapeutic options offered by target therapy and immunotherapy in relapsing patients, the role of radiological investigations in the follow-up of stage 2A patients should be reconsidered.